Influenza virus vaccine - Sinovac Biotech

Drug Profile

Influenza virus vaccine - Sinovac Biotech

Alternative Names: Anflu; Influenza Vaccine (Split Virion), Inactivated - Sinovac Biotech; Split influenza virus vaccine - Sinovac Biotech

Latest Information Update: 31 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sinovac Biotech
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 31 Dec 2017 Sinovac Biotech has patent protection for influenza virus vaccine in China
  • 23 Mar 2015 The vaccine is approved in Hong Kong and is awaiting approval in India for influenza virus infections
  • 14 Aug 2014 Launched for Influenza virus infections (Prevention) in Mexico before August 2014 (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top